CRA provided expert reports and trial testimony in trade secret litigation concerning an early-stage oncology product candidate. Plaintiff claimed that the alleged misappropriation led to accelerated development of a competing potential treatment. CRA quantified unjust enrichment using a methodology that measured the value associated with accelerated development, recognizing advantages associated with early versus late entry into the marketplace.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...